Abstract
The multifunctional human Parkinson's disease protein 7 (PARK7/DJ1) is an attractive therapeutic target due to its link with early-onset Parkinson's disease, upregulation in various cancers, and contribution to chemoresistance. However, only a few compounds have been identified to bind PARK7 due to the lack of a dedicated chemical toolbox. We report the creation of such a toolbox and showcase the application of each of its components. The selective PARK7 submicromolar inhibitor with a cyanimide reactive group covalently modifies the active site Cys106. Installment of different dyes onto the inhibitor delivered two PARK7 probes. The Rhodamine110 probe provides a high-throughput screening compatible FP assay, showcased by screening a compound library (8000 molecules). The SulfoCy5-equipped probe is a valuable tool to assess the effect of PARK7 inhibitors in a cell lysate. Our work creates new possibilities to explore PARK7 function in a physiologically relevant setting and develop new and improved PARK7 inhibitors.
Cite
CITATION STYLE
Jia, Y., Kim, R. Q., Kooij, R., Ovaa, H., Sapmaz, A., & Geurink, P. P. (2022). Chemical Toolkit for PARK7: Potent, Selective, and High-Throughput. Journal of Medicinal Chemistry, 65(19), 13288–13304. https://doi.org/10.1021/acs.jmedchem.2c01113
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.